Inflarx N V (IFRX) - News Archive

On February 13, 2025, InflaRx N.V. (Nasdaq: IFRX), based in Jena, Germany, announced the pricing of its underwritten public offering, aimed at raising approximately $30 million. The offering includes 8.25 million ordina...

InflaRx N.V. Announces Public Offering of Ordinary Shares and Pre-Funded Warrants: What It Means for ShareholdersInflaRx N.V. (Nasdaq: IFRX), the biopharmaceutical leader known for its pioneering work in anti-inflammato...

InflaRx Gains Ground in ARDS Treatment: GOHIBIC Approved by European CommissionOn January 15, 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, announced a si...

In a significant advancement towards integrating innovative therapeutics into the treatment landscape of chronic inflammatory diseases, InflaRx N.V. has announced that the first patient has been dosed in its Phase 2a ba...

In a significant stride toward expanding therapeutic options for severe COVID-19 complications, InflaRx N.V. has announced that its novel anti-inflammatory drug, GOHIBIC (vilobelimab), has received a positive opinion fr...

InflaRx Expands Horizon of Anti-Inflammatory Therapies with New Data on INF904 Biopharmaceutical innovation continues to gain momentum, especially in the realm of anti-inflammatory therapeutics targeting the complement...

Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by severe inflammation in the lungs, leading to respiratory failure. It is a significant cause of mortality and morbidity worldwid...

Advancements in Combating Severe COVID-19: Potential Synergy of Vilobelimab in Combination with Other Immunomodulators:The ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) h...

1. Article for :InflaRx, a pioneering biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system, is set to make a significant announcement concerning its upcoming dev...

InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory therapeutics targeting the complement system, has recently introduced the InflaRx Commitment Prog...

Inflammation is a complex immune response that plays a crucial role in various diseases, including autoimmune disorders. Targeting the complement system, a key mediator of inflammation, has emerged as a promising therap...